Effect of KRAS oncogene substitutions on protein behavior: Implications for signaling and clinical outcome

Journal of the National Cancer Institute

Volumn 104, Issue 3, 2012, Pages 228-239

  Ihle, Nathan T ^a   Byers, Lauren A ^b   Kim, Edward S ^b   Saintigny, Pierre ^b   Lee, J Jack ^b   Blumenschein, George R ^b   Tsao, Anne ^b   Liu, Suyu ^b   Larsen, Jill E ^b   Wang, Jing ^b   Diao, Lixia ^b   Coombes, Kevin R ^b   Chen, Lu ^a   Zhang, Shuxing ^a   Abdelmelek, Mena F ^a   Tang, Ximing ^b   Papadimitrakopoulou, Vassiliki ^b   Minna, John D ^b   Lippman, Scott M ^b   Hong, Waun K ^b   Herbst, Roy S ^b   Wistuba, Ignacio I ^b,c   Heymach, John V ^b   Powis, Garth ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; ERLOTINIB; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SORAFENIB; TRANSCRIPTOME; VANDETANIB;

AMINO ACID SUBSTITUTION; ARTICLE; BRONCHUS MUCOSA; CONTROLLED STUDY; EPITHELIUM CELL; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; ONCOGENE K RAS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ASPARTIC ACID; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE II AS TOPIC; CYSTEINE; DISEASE-FREE SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GENETIC VECTORS; GLYCINE; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; LENTIVIRUS; LUNG NEOPLASMS; MICROARRAY ANALYSIS; MOLECULAR TARGETED THERAPY; MUTATION; PROTO-ONCOGENE PROTEINS C-AKT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; VALINE;

EID: 84863116014     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr523     Document Type: Article

References (29)

1. Kranenburg O. The KRas oncogene: past, present and future. Biochim Biophys Acta. 2005;1756(2):81-82. (Pubitemid 41773135)
2. Raponi M, Winkler H, Dracopoli N. KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol. 2008;8(4):413-418.
3. Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol. 2009;6(9):528-534.
4. Capella G, Cronauer-Mitra S, Peinado MA, Perucho M. Frequency and spectrum of mutations at codons 12 and 13 of the C-K-ras gene in human tumors. Environ Health Perspect. 1991;93:125-131.
5. Poorta M, Crous-Bou M, Wark PA, et al. Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes. Mutat Res. 2009;682(2-3):83-93.
6. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: a multicenter "RASCAL" study. J Nat Cancer Inst. 1998;90(9):675-684. (Pubitemid 28222141)
7. Siegfried JM, Gillespie AT, Mera R, Casey TJ, Keohavong P, Testa JR. Prognostic value of specific KRAS mutations in lung adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 1997;6(10):841-847. (Pubitemid 27435484)
8. Hunt JD, Strimas A, Martin JE, et al. Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens. Cancer Epidemiol Biomarkers Prev. 2002;11(11):1405-1412. (Pubitemid 35340377)
9. Cully M, Downward J. SnapShot: Ras signaling. Cell. 2008;133(7):1292- 1292.e1.
10. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1(1):44-53.
11. Shames DS, Girard L, Gao B, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006;3(12):e486.
12. Sullivan JP, Spinola M, Dodge M, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 2010;70(23):9937-9948.
13. Sato M, Vaughan MB, Girard L, et al. Multiple oncogenic changes (K-RAS[V12], p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res. 2006;66(4):2116-2128.
14. Vikis H, Sato M, James M, et al. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res. 2007;67(10):4665-4670. (Pubitemid 46910171)
15. Pacold ME, Suire S, Perisic O, et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell. 2000;103(6):931-943.
16. Huang L, Hofer F, Martin GS, Kim SH. Structural basis for the interaction of Ras with RalGDS. Nat Struct Biol. 1998;5(6):422-426. (Pubitemid 28265022)
17. Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26(16):1781-1802. (Pubitemid 43078511)
18. Gorfe AA, Grant BJ, McCammon JA. Mapping the nucleotide and isoform-dependent structural and dynamical features of Ras proteins. Structure. 2008;16(6):885-896. (Pubitemid 351778381)
19. Seeber M, Cecchini M, Rao F, Settanni G, Caflisch A, Wordom A. A program for efficient analysis of molecular dynamics simulations. Bioinformatics. 2007;23(19):2625-2627. (Pubitemid 350048368)
20. Pierce B, Weng ZP. ZRANK: reranking protein docking predictions with an optimized energy function. Proteins. 2007;67(4):1078-1086. (Pubitemid 46753952)
21. Dunlop EA, Tee AR. Mammalian target of rapamycin 1: signaling inputs, substrates and feedback mechanisms. Cell Signal. 2009;21(6):827-835.
22. Garassino MC, Marabese M, Rusconi P, et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol. 2011;22(1):235-237.
23. Fan J, Bertino J. KRas modulates the cell cycle via both positive and negative regulatory pathways. Oncogene. 1997;14(21):2595-2607. (Pubitemid 27273521)
24. Drosten M, Dhawahir A, Sum E, et al. Genetic analysis of Ras signaling pathways in cell proliferation, migration, and survival. EMBO J. 2010;29(6):1091-1104.
25. Hamad NM, Elconin JH, Kamoub AE, et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 2002;16(16):2045-2057.
26. Tuveson DA, Shaw AT, Willis NA, et al. Endogenous oncogenic KRas (G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell. 2004;5(4):375-387. (Pubitemid 38482073)
27. Floyd HS, Farnsworth CL, Kock ND, et al. Conditional expression of the mutant Ki-Ras G12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model. Carcinogenesis. 2005;26(12):2196-2206. (Pubitemid 41672208)
28. Dance-Barnes ST, Kock ND, Floyd HS, et al. Effects of mutant human Ki-Ras (G12C) gene dosage on murine lung tumorgenesis and signaling to downstream effectors. Toxicol Appl Pharmacol. 2008;231(12):77-84.
29. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500-1508. (Pubitemid 43259931)